The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer
- PMID: 15473502
- DOI: 10.1023/B:QURE.0000037494.27127.b5
The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer
Abstract
Purpose: To examine the relationship between changes in health-related quality-of-life (HRQOL) on the EORTC Quality of Life Questionnaire (QLQ-C30), and patients' perceptions of HRQOL changes as measured by the Subjective Significance Questionnaire (SSQ).
Patients and methods: A total of 101 patients completed the QLQ-C30 on weeks 1, 4 and 7 of radical external-beam radiation therapy (RT) for localized cancer of the prostate. Patients rated their change in physical functioning, emotional functioning, social functioning, and overall/global quality of life (QOL) by completing a seven-category SSQ at weeks 4 and 7. The association between changes in the QLQ-C30 change and the corresponding SSQ ratings were determined by calculation of mean change scores for each SSQ category and by Spearman rank correlation coefficient analysis.
Results: Patients' completion of the QLQ-C30 and SSQ exceeded 95%. Statistically significant changes in fatigue, pain, appetite, diarrhea, and global QOL scores were detected during RT. For patients reporting 'a little' change in global QOL on the SSQ, absolute mean QLQ-C30 change scores ranged between 0 to 15 points with 12/16 mean change scores between 2.5 and 8.5 points. In the entire study sample, correlations between SSQ patient ratings and QLQ-C30 change scores were lower than previously reported, ranging between 0.15 and 0.24 for the four different domains, but were higher when QOL scores producing ceiling effects were omitted.
Conclusion: The SSQ and QLQ-C30 may measure related concepts that could assist in the interpretation of changes in scores and in the calibration of the QLQ-C30. However, the nature of this relationship could not be elucidated in this data set because of a lack of variance in HRQOL scores in the study sample. Further investigation should be carried out in study samples with sufficient variance to allow more robust conclusions.
Similar articles
-
Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy.BMC Cancer. 2013 Mar 28;13:165. doi: 10.1186/1471-2407-13-165. BMC Cancer. 2013. PMID: 23537330 Free PMC article. Clinical Trial.
-
Interpreting the significance of changes in health-related quality-of-life scores.J Clin Oncol. 1998 Jan;16(1):139-44. doi: 10.1200/JCO.1998.16.1.139. J Clin Oncol. 1998. PMID: 9440735
-
Interpreting the Significance of Changes in Health-Related Quality-of-Life Scores.J Clin Oncol. 2023 Dec 10;41(35):5345-5350. doi: 10.1200/JCO.22.02776. J Clin Oncol. 2023. PMID: 38056079
-
Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30.Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):831-7. doi: 10.1586/erp.12.70. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 23252363 Review.
-
Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series.Health Qual Life Outcomes. 2018 Jan 22;16(1):21. doi: 10.1186/s12955-018-0844-8. Health Qual Life Outcomes. 2018. PMID: 29357874 Free PMC article. Review.
Cited by
-
Describing the minimally clinically important difference of a chemotherapy-induced peripheral neuropathy patient-reported outcome measure in young adults.Asia Pac J Oncol Nurs. 2025 Jan 19;12:100656. doi: 10.1016/j.apjon.2025.100656. eCollection 2025 Dec. Asia Pac J Oncol Nurs. 2025. PMID: 40007520 Free PMC article.
-
Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer.Qual Life Res. 2007 May;16(4):571-5. doi: 10.1007/s11136-006-9156-2. Epub 2007 Feb 10. Qual Life Res. 2007. PMID: 17294287
-
Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy.BMC Cancer. 2013 Mar 28;13:165. doi: 10.1186/1471-2407-13-165. BMC Cancer. 2013. PMID: 23537330 Free PMC article. Clinical Trial.
-
Prospective evaluation of fatigue during a course of curative radiotherapy for localised prostate cancer.Support Care Cancer. 2007 Oct;15(10):1169-76. doi: 10.1007/s00520-007-0229-8. Epub 2007 Mar 1. Support Care Cancer. 2007. PMID: 17333296
-
Low incidence of fatigue after hypofractionated stereotactic body radiation therapy for localized prostate cancer.Front Oncol. 2012 Oct 17;2:142. doi: 10.3389/fonc.2012.00142. eCollection 2012. Front Oncol. 2012. PMID: 23087903 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical